The fulminant form of pseudomembranous colitis in a child with cystic fibrosis

Аnnotation. A long-term persistent infection of the lower respiratory tract with cystic fibrosis and, as a consequence, the need for regular use of antibacterial drugs inevitably leads to changes in the composition of the intestinal microflora. At the same time, the most dangerous are toxigenic strains of Clostridium difficile. In turn, excessive growth of C. Difficile leads to increased sensitivity of enterocytes to its toxins. The leading pathogenicity factors of C. Difficile are exotoxins A (TcdA), B (TcdB) and binary toxin. TcdA and TcdB are enterotoxins acting on intestinal enterocytes, which leads to inflammation and necrosis of the mucous membrane. The binary toxin forms a complex on the enterocyte membrane that penetrates the cytoplasm, disrupts the functioning of the cell, leads to its death, and also enhances the adhesion and colonization of C. Difficile. One of the most accessible methods for determining the presence of toxin-producing C. Difficile in feces is immunochromatographic examination. The frequency of such a complication in patients with MV is unknown, the literature presents isolated cases of such a complication in Russia. There is one known case of fulminant pseudomembranous colitis (lethal). A clinical case of fulminant pseudomembranous colitis with recovery is presented. Conclusion. Patients with cystic fibrosis are at risk for the development of this complication, especially patients with a history of intestinal resection against the background of meconium ileus. In about 5% of cases, there is a fulminant course of pseudomembarnous colitis. In this form, the duration of the disease can be several hours. Lethality in the lightning-fast course reaches 58-70%. This option presents the greatest difficulty in terms of diagnosis due to atypical clinical symptoms. In particular, the diarrheal syndrome may not be pronounced or absent at all. Such patients often show symptoms of an acute abdomen, which makes differential diagnosis difficult. This is confirmed in our clinical case. It is necessary to increase awareness and alertness of doctors regarding the risk of developing this formidable complication in patients with Сystic fibrosis

cystic fibrosis, children, enterocolitis, Clostridium difficile, pseudomembranous colitis

1. [CYSTIC FIDOSIS]. edd by N. Yu. Kashirskaya, N. I. Kapranov and E. I. Kondratyeva. [2nd edition, revised and expanded]. Moscow. Publishing House “MEDPRACTICA-M”, 2021, 680 p. (in Russ.) ISBN 978-5-98803-450-6.@@ МУКОВИСЦИДОЗ. Издание 2-е., переработанное и дополненное (под редакцией Н. Ю. Каширской, Н. И. Капранова и Е. И. Кондратьевой). - М.: ИД «МЕДПРАКТИКА-М», 2021, 680 с. ISBN 978-5-98803-450-6

2. Kondratyeva E.I., Kashirskaya N. Yu., Kapranov N. I. [National consensus. Cystic fibrosis: definition, diagnostic criteria, therapy]. Moscow. 2019. 356 p. (in Russ.)@@ Кондратьева Е. И., Каширская Н. Ю., Капранов Н. И. Национальный консенсус. Муковисцидоз: определение, диагностические критерии, терапия. М. 2019. 356 с.

3. [Clinical guidelines “Cystic fibrosis (cystic fibrosis)” age group - adults and children]. 2021, No: KR372/1. (in Russ.)@@ Клинические рекомендации «Кистозный фиброз (муковисцидоз)» (возрастная группа - взрослые и дети) 2021, КР372/1.

4. Turck D., Braegger C. P., Colombo C. et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016 Jun;35(3):557-77. doi: 10.1016/j.clnu.2016.03.004.

5. Shelygin Yu. A., Aleshkin V. A., Selkova E. P., Mironov A. Yu., Grenkova T. A., Shelygin Yu.A., Sukhina M. A., Achkasov S. I., Safin A. L. [Laboratory diagnosis of Clostridium difficile-associated diarrhea]. Federal clinical guidelines. Moscow. 2017, 24 P. (in Russ.)@@ Шелыгин Ю. А., Алёшкин В. А., Селькова Е. П., Миронов А. Ю., Гренкова Т. А., Шелыгин Ю. А., Сухина М. А., Ачкасов С. И., Сафин А. Л. Лабораторная диагностика Clostridium difficile-ассоциированных диарей. Федеральные клинические рекомендации. М., 2017; 24 с

6. McDonald L.C., Gerding D. N., Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.

7. Kondratenko O.V., Lyamin A. V., Vasil’eva E.A., Zheleznova E. A. Rare complications of therapy of cystic fibrosis: clostridium difficile-associated colitis. PULMONOLOGIYA. 2016;26(5):556-559. (In Russ.) doi: 10.18093/0869-0189-2016-26-5-556-559.@@ Кондратенко О. В., Лямин А. В., Васильева Е. А., Железнова Е. А. Редкие осложнения терапии муковисцидоза: clostridium difficile-ассоциированный колит. Пульмонология. 2016;26(5):556-559. doi: 10.18093/0869-0189-2016-26-5-556-559.

8. Egressy K., Jansen M., Meyer K. C. Recurrent Clostridium difficile colitis in cystic fibrosis: an emerging problem. J Cyst Fibros. 2013 Jan;12(1):92-6. doi: 10.1016/j.jcf.2012.05.007.

9. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002: Mar;235(3):363-72. doi: 10.1097/00000658-200203000-00008.

10. Nikolaeva I.V., Shestakova I. V., Murtazina G. K. Current strategies for diagnosis and treatment of Clostridium difficile-infection (literature review). Acta Biomedica Scientifica. 2018;3(1):34-42. (In Russ.) doi: 10.29413/ABS.2018-3.1.5.@@ Николаева И. В., Шестакова И. В., Муртазина Г. Х. Современные стратегии диагностики и лечения Clostridium difficile-инфекции (обзор литературы). Acta Biomedica Scientifica. 2018:3(1):34-42. doi: 10.29413/ABS.2018-3.1.5.